Claroty

Has expanded from pure ICS into healthcare (Medigate) and enterprise IoT over roughly a decade, broadening its detection and asset-coverage engineering steadily rather than in sudden leaps.

Agentless discovery across industrial, medical and building systems gives security teams a single risk view over device classes that are otherwise invisible to standard IT tooling.

Independently verified: $150M Series F at a $3B valuation (Jan 2026), $882M total funding, and 24 of the Fortune 100 as customers, reported across multiple financial and trade press outlets. Recognized in Cyber Defense Media Group's 2026 Global InfoSec Awards (1 award), independently juried industry validation of market traction.

Unifying industrial, medical device and building IoT security under one platform is a genuinely broader approach than single-vertical CPS tools, earning the top Gartner MQ position, though it remains an evolution of asset-visibility security rather than a wholesale reinvention. However, Claroty raised a $150M Series F at a $3B valuation in January 2026 (per securityweek.com), which is the scale of an established incumbent rather than an emerging category disruptor, so this dimension is scored more conservatively.

Ranked highest of all vendors in the 2026 Gartner Magic Quadrant for CPS Protection Platforms on both execution and vision axes, a credible independent signal, though public red-team or incident-response case data is limited.

Convergence of IT, OT, medical and building systems under attack will keep growing as critical infrastructure and healthcare digitize further over the next several years.